Structure-Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae. 2021

Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States.

Neisseria gonorrhoeae is an urgent threat to public health in the United States and around the world. Many of the current classes of antibiotics to treat N. gonorrhoeae infection are quickly becoming obsolete due to increased rates of resistance. Thus, there is a critical need for alternative antimicrobial targets and new chemical entities. Our team has repurposed the FDA-approved carbonic anhydrase inhibitor scaffold of acetazolamide to target N. gonorrhoeae and the bacteria's essential carbonic anhydrase, NgCA. This study established both structure-activity and structure-property relationships that contribute to both antimicrobial activity and NgCA activity. This ultimately led to molecules 20 and 23, which displayed minimum inhibitory concentration values as low as 0.25 μg/mL equating to an 8- to 16-fold improvement in antigonococcal activity compared to acetazolamide. These analogues were determined to be bacteriostatic against the pathogen and likely on-target against NgCA. Additionally, they did not exhibit any detrimental effects in cellular toxicity assays against both a human endocervical (End1/E6E7) cell line or colorectal adenocarcinoma cell line (Caco-2) at concentrations up to 128 μg/mL. Taken together, this study presents a class of antigonococcal agents with the potential to be advanced for further evaluation in N. gonorrhoeae infection models.

UI MeSH Term Description Entries
D009344 Neisseria gonorrhoeae A species of gram-negative, aerobic bacteria primarily found in purulent venereal discharges. It is the causative agent of GONORRHEA. Diplococcus gonorrhoeae,Gonococcus,Gonococcus neisseri,Merismopedia gonorrhoeae,Micrococcus der gonorrhoe,Micrococcus gonococcus,Micrococcus gonorrhoeae
D002257 Carbonic Anhydrase Inhibitors A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. Carbonate Dehydratase Inhibitor,Carbonate Dehydratase Inhibitors,Carbonic Anhydrase Inhibitor,Carboxyanhydrase Inhibitor,Carboxyanhydrase Inhibitors,Anhydrase Inhibitor, Carbonic,Dehydratase Inhibitor, Carbonate,Inhibitor, Carbonate Dehydratase,Inhibitor, Carbonic Anhydrase,Inhibitor, Carboxyanhydrase,Inhibitors, Carbonate Dehydratase,Inhibitors, Carbonic Anhydrase,Inhibitors, Carboxyanhydrase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086 Acetazolamide One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) Acetadiazol,Acetazolam,Acetazolamide Sodium, (Sterile),Acetazolamide, Monosodium Salt,Ak-Zol,Apo-Acetazolamide,Diacarb,Diamox,Diuramide,Défiltran,Edemox,Glauconox,Glaupax,Huma-Zolamide,Ak Zol,AkZol,Apo Acetazolamide,ApoAcetazolamide,Huma Zolamide,HumaZolamide
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D018938 Caco-2 Cells Human colonic ADENOCARCINOMA cells that are able to express differentiation features characteristic of mature intestinal cells, such as ENTEROCYTES. These cells are valuable in vitro tools for studies related to intestinal cell function and differentiation. Caco 2 Cells,Caco-2 Cell,Cell, Caco-2,Cells, Caco-2

Related Publications

Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
January 1998, Journal of molecular biology,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
May 2024, Journal of medicinal chemistry,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
January 1966, Antimicrobial agents and chemotherapy,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
March 2001, European journal of biochemistry,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
July 1992, Journal of medicinal chemistry,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
January 2023, ACS medicinal chemistry letters,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
February 1997, Infection and immunity,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
January 2003, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
December 2012, Journal of enzyme inhibition and medicinal chemistry,
Chad S Hewitt, and Nader S Abutaleb, and Ahmed E M Elhassanny, and Alessio Nocentini, and Xufeng Cao, and Devon P Amos, and Molly S Youse, and Katrina J Holly, and Anil Kumar Marapaka, and Weiwei An, and Jatinder Kaur, and Aaron D Krabill, and Ahmed Elkashif, and Yehia Elgammal, and Amanda L Graboski, and Claudiu T Supuran, and Mohamed N Seleem, and Daniel P Flaherty
October 1969, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!